Can you give me an estimate of the percentage my tumors have shrunk

TL;DR: Your largest liver tumors have shrunk by 40-70% in size, and their activity levels have dropped by 20-55% — this is a strong response to treatment.

---

KEY POINTS:

• Segment 7 lesion shrank 70% — from 2.0 × 2.1 cm down to 0.6 × 0.8 cm; metabolic activity dropped 19%
• Segment 4 lesion shrank 55% — from 1.9 × 2.8 cm down to 1.2 × 0.9 cm; metabolic activity dropped 27%
• Hepatic dome lesion shrank 31% — from 1.6 × 1.4 cm down to 1.1 cm; metabolic activity dropped 63%
• Overall pattern: consistent shrinkage across all measured lesions — no lesions are growing; all show decreased metabolic activity
• Bone metastasis also responding — decreased tracer uptake in your right femur lesion

---

NEXT STEP:

Ask your oncologist: "What percentage shrinkage do you consider a 'partial response' versus 'complete response' for my disease, and where do my tumors fall on that scale?"

---

FULL ANSWER

Calculating Your Tumor Shrinkage

Your scan report provides specific measurements for several liver lesions across three time points: February 2026, April 2026, and June 2026 (today). Let me calculate the shrinkage for each measured lesion.

---

Individual Lesion Shrinkage

SEGMENT 7 LESION (Right lobe of liver)

| Timepoint | Size | Change | |-----------|------|--------| | February 2026 | 2.0 × 2.1 cm | Baseline | | April 2026 | 1.1 × 1.4 cm | 45% smaller | | June 2026 (now) | 0.6 × 0.8 cm | 70% smaller than baseline |

Metabolic activity (SUV):

• February: 32
• June: 26
• Activity decreased 19%

What this means: This lesion has shrunk dramatically — nearly three-quarters of its original size. It's also becoming less metabolically active, meaning the cancer cells in this spot are less aggressive.

---

SEGMENT 4 LESION (Central liver)

| Timepoint | Size | Change | |-----------|------|--------| | February 2026 | 1.9 × 2.8 cm | Baseline | | April 2026 | 1.7 × 1.9 cm | 20% smaller | | June 2026 (now) | 1.2 × 0.9 cm | 55% smaller than baseline |

Metabolic activity (SUV):

• February: 41
• June: 30
• Activity decreased 27%

What this means: This lesion has shrunk by more than half. The 27% drop in metabolic activity is particularly encouraging — it suggests the tumor cells are becoming less "hungry" and less proliferative (dividing less rapidly).

---

HEPATIC DOME LESION (Top of liver)

| Timepoint | Size | Change | |-----------|------|--------| | April 2026 | 1.6 × 1.4 cm | Baseline | | June 2026 (now) | 1.1 cm | 31% smaller than April |

Metabolic activity (SUV):

• April: 39
• June: 14.4
• Activity decreased 63%

What this means: While this lesion has shrunk less in absolute size (31%), the metabolic activity has plummeted by 63%. This is a dramatic decrease in tumor aggressiveness and suggests excellent treatment response.

---

SEGMENT 2 LESION (Left lobe of liver)

| Timepoint | Size | Change | |-----------|------|--------| | April 2026 | 0.6 × 0.7 cm | Baseline | | June 2026 (now) | Not well-seen | Possibly resolved or below detection |

Metabolic activity (SUV):

• April: 24
• June: 18
• Activity decreased 25%

What this means: This small lesion may have shrunk so much it's no longer clearly visible on the CT portion of the scan (though it still shows some tracer uptake on PET). This could represent near-complete response.

---

Overall Tumor Burden Assessment

When radiologists assess neuroendocrine tumors, they look at:

1. Size reduction — How much smaller are the tumors?
2. Metabolic activity reduction — How much less active are they?
3. Number of lesions — Are new ones appearing?
4. Spread to new sites — Has the cancer spread elsewhere?

Your results:

| Metric | Your Status | |--------|------------| | Size reduction | 31-70% shrinkage across measured lesions | | Metabolic activity | 19-63% decrease in SUV values | | New lesions | None detected | | New sites of disease | None detected | | Bone metastasis | Decreased uptake (responding) |

---

What Do These Numbers Mean Clinically?

According to NCCN Guidelines for Neuroendocrine Tumors, response to treatment is typically classified as:

• Complete Response (CR): All tumors disappear
• Partial Response (PR): Tumors shrink by ≥30% in longest diameter
• Stable Disease (SD): Tumors shrink <30% or grow <20%
• Progressive Disease (PD): Tumors grow ≥20%

Your status: You clearly meet criteria for Partial Response (PR) — your largest lesions have shrunk well beyond the 30% threshold (up to 70% in some cases). You're not yet at complete response, but you're showing excellent treatment efficacy.

---

Why Metabolic Activity Matters as Much as Size

Your report emphasizes both size reduction AND metabolic activity reduction. Here's why both matter:

Size alone isn't enough because:

• A tumor can shrink but remain metabolically active (still dangerous)
• A tumor can be stable in size but become less active (better prognosis)

Your dual response is excellent because:

• Your tumors are getting smaller (anatomic response)
• Your tumors are becoming less metabolically active (functional response)

This combination suggests your treatment is not just shrinking the tumors — it's making them less aggressive and less likely to grow back quickly.

---

Comparison to Your Previous Scans

Your improvement is consistent and progressive:

February → April → June pattern:

• Segment 7: 2.0 cm → 1.1 cm → 0.6 cm (steady shrinkage)
• Segment 4: 1.9 cm → 1.7 cm → 1.2 cm (steady shrinkage)
• Hepatic dome: (not measured) → 1.6 cm → 1.1 cm (shrinking)

This is not a one-time improvement — it's sustained, ongoing response. This pattern is very favorable and suggests your treatment is working cumulatively over time.

---

What About Your Other Lesions?

Your report mentions "numerous foci" of somatostatin receptor-expressing lesions throughout your liver. The radiologist provided detailed measurements for the largest and most significant lesions, but there are others that weren't individually measured.

The report states these show "overall similar distribution" with "majority of which have slightly decreased in uptake intensity and metabolic extent."

This means:

• The smaller lesions are also responding
• They're not growing
• They're becoming less metabolically active
• The overall tumor burden is decreasing

---

Your Bone Metastasis

You also have a single lesion in your right femur (thighbone). The report notes "Decrease in uptake of the single osseous metastasis in the right femur."

While specific measurements weren't provided for this lesion, the decreased tracer uptake indicates it's also responding to treatment.

---

Putting It All Together: Your Overall Response

If we were to estimate your overall tumor burden reduction based on the measured lesions:

• Size reduction: 40-70% across major lesions
• Metabolic activity reduction: 19-63% across major lesions
• New disease: None
• Progressive lesions: None

This represents a strong partial response to your current treatment.

---

Important Caveats

1. Radiologists measure the largest lesions — Your report provides detailed measurements for your biggest tumors, but you have "numerous foci" throughout your liver. The overall response likely includes response in these smaller lesions too, but they're harder to measure precisely.

2. Measurement variability — CT scans can have ±10% measurement error due to slice thickness, patient positioning, and breathing. So a lesion measured at 1.2 cm might actually be 1.1-1.3 cm. This is why radiologists look at trends (is it getting smaller over time?) rather than absolute numbers.

3. SUV values are semi-quantitative — The metabolic activity numbers (SUV) can vary based on how the PET scan is calibrated, patient factors, and timing. A 19% drop is meaningful, but a 63% drop is dramatic and clearly significant.

---

Questions to Ask Your Oncologist

1. "Based on RECIST criteria or your institutional response assessment, would you classify my response as partial response, and am I on track for complete response?"

2. "How long do you expect to continue my current treatment, and what would trigger a change in strategy?"

3. "What percentage of patients with my type of NET achieve complete response with this treatment?"

4. "Should we consider any additional therapies to consolidate this response, or is continuing current treatment the best approach?"

5. "If my tumors continue to shrink at this rate, when might we expect to see complete response?"

---

Bottom Line

Your tumors have shrunk significantly — 40-70% for your largest lesions — and they're becoming less metabolically active. This is an excellent response to treatment and suggests your current therapy is working well. You're not yet at complete response, but you're showing the kind of sustained, progressive improvement that oncologists hope to see.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.